Diagnosing Dx

What If the Patients Who Need Your Test Are Already Hiding in the EHR? Sagacity Diagnostics

In this episode of Diagnosing Dx, David Filby is joined by Raymond Tarr, Founder of Sagacity Diagnostics. Raymond brings more than 25 years of experience across diagnost

Can Strategic Partnerships Save Diagnostics Innovation? Robert Carlson

In this episode of Diagnosing Dx, David Filby is joined by Robert Carlson, Founder and President of Life Science Dx Consulting. Robert brings 30 years of experience acro

Could More Frequent Blood Testing Transform How We Detect Disease?

In this episode of Diagnosing Dx, David Filby is joined by Octavian Florescu, CEO of In Diagnostics. An electrical engineer and microchip designer by training, Octavian

Why Are Vector-Borne Infections Still So Difficult to Diagnose?

In this episode of Diagnosing Dx, David Filby is joined by Nicole Bell, CEO of Galaxy Diagnostics. Nicole’s route into vector-borne disease diagnostics is deeply persona

What Can Diagnostics Founders Learn From Two Successful Exits? Andrew Miller

In this episode of Diagnosing Dx, David Filby is joined by Andrew Miller, a diagnostics founder, advisor and two-time exited CEO. A scientist by training, Andrew founded

98% of Cancer Patients Outside the US Miss Genomic Testing. Can AI Change That?

In this episode of Diagnosing Dx, David Filby is joined by Travis Wold, Chief Executive Officer at Imagenomix. Travis brings experience across cancer diagnostics, genomi

Could 20-Minute Hormone Testing Transform Patient Care? Nedal Safwat, SVP at Canatu

In this episode of Diagnosing Dx, David Filby is joined by Nedal Safwat, Senior Vice President of Medical Diagnostics at Canatu and President of Canatu Inc. With more th

Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

In this episode of Diagnosing Dx, David Filby is joined by Dean Remy, Co-Founder and Chief Commercial Officer at Mativa Diagnostics. Dean brings 35 years of experience a

Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

In this episode of Diagnosing Dx, David Filby is joined by Thomas Briggs, Chief Growth Officer at RedDrop Dx. Thomas brings more than 25 years of diagnostics and healthc

Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

In this episode of Diagnosing Dx, David Filby is joined by Alec Ford, Chief Executive Officer at Karius. Alec brings decades of leadership experience across therapeutics

Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build Bo

What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire. Talia is a neuroscientist by training who spent more than a decade in ac

Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.   Bharat has led Helio Genomics since July 2025, bringing dec

The EU Market Access Playbook for Diagnostics Companies - Svetlana Nikic

In this episode of Diagnosing Dx, I’m joined by Svetlana Nikic, Founder of Precision Oncology Consulting.Svetlana shares her journey from Roche and Illumina into building

The Future of Kidney Transplant Monitoring: Moving Beyond Biopsies - Sara Barrington, CEO of Verici Dx

In this episode of Diagnosing Dx, I’m joined by Sara Barrington, CEO at Verici Dx. Sara explains how Verici Dx is tackling one of the biggest unresolved problems in kidn

How Cleveland Diagnostics Is Redefining Prostate Cancer Testing

In this episode of Diagnosing Dx, I’m joined by Arnon Chait, PhD, MBA, Chief Innovation Officer at Cleveland Diagnostics.Arnon shares his journey from NASA physicist to d

The New Rules of Diagnostics: Lean Teams, Faster Revenue, Smarter Growth - MJ Hymes, i5 BioPartners

In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of li

“Wait and Watch” Is Failing Cancer Patients — Harbinger Health on What Comes Next

In this episode of Diagnosing Dx, I’m joined by Ajit Singh, CEO at Harbinger Health.Ajit has spent decades building, scaling, and investing in diagnostics companies, and

Reimbursement-First Thinking in Early-Stage Diagnostics with OraLiva

In this episode of Diagnosing Dx, I’m joined by ⁠Spencer Price⁠, Chief Executive Officer at ⁠OraLiva⁠, a company building an AI-powered precision diagnostic designed to t

The 20-Year Head Start: How Amprion Is Transforming Neurodiagnostics

In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheim